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Abstract 
 
Background 
Children with neurodevelopmental disabilities (ND) may be at risk of opioid induced 
respiratory depression (OIRD). We aimed to quantify the risks & effectiveness of morphine-
NCA for postoperative pain in children with ND. 
 
Methods 
A retrospective cohort study of 12,904 postoperative children who received intravenous 
morphine-NCA. Subjects were divided into neurodevelopmental disability (NDG) and 
control groups (CG). Rates of clinical satisfaction, respiratory depression (RD) and serious 
adverse events (SAE) were obtained and statistical analysis including multilevel logistic 
regression using Bayesian inference was performed.  
 
Results 
2,390 of 12,904 patients (19%) had ND. There were 88 cases of RD and 52 SAEs; there were 
no opioid-related deaths. The cumulative incidence of RD in the NDG was 1.09% vs 0.59% 
in the CG, OR 1.8 (98% chance that the true odds ratio was >1). A significant interaction 
between postoperative morphine dose and ND was observed, with higher risk of RD with 
increasing dose. Satisfaction with morphine-NCA was very high overall, although children 
with ND were 1% more likely to have infusions rated as fair or poor (3.3% vs 2.1%, χ2 
p<0.001). 
 
 
 
3 
Conclusions 
Children with ND were 1.8 times more likely to suffer RD, absolute risk difference 0.5%; 
OIRD in this group may relate to increased sensitivity to dose-related effects of morphine. 
Morphine-NCA as described was a safe & acceptable technique for children with ND & 
controls, but further evaluation of the effects of opioids in this vulnerable group are indicated.  
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Introduction 
Intravenous opioids are frequently used for the management of severe postoperative pain in 
children and are generally considered to have an acceptable safety profile.
1-4
 However, some 
patient groups may be at increased risk of opioid-induced respiratory depression (OIRD), a 
potentially life-threatening side-effect.
5
 Neonates, especially premature neonates, children 
with obstructive sleep apnoea (OSA), or renal impairment (RI), are thought to be at higher 
risk of OIRD; it is therefore important to identify such patients and institute appropriate 
monitoring if opioids are to be used with optimum safety.
2-5
 
 
Children with neurodevelopmental disabilities (ND) are a large and important group in whom 
the challenges of effective and safe pain management are recognised. Communication 
difficulties, physical and physiological impairments, pharmacokinetic-pharmacodynamic 
differences and drug interactions add to the complexity of pain management in this group and 
may contribute to the suggestion that they are more susceptible to OIRD; however few data 
are available.
3, 6-16
 High frequency of pain in children with ND and their increased likelihood 
to undergo surgery,
7, 17
 shows a clear need for better understanding of analgesic effects in 
these vulnerable young people.
7,21
 
 
We aimed to quantify the risks of respiratory depression (RD), serious adverse events (SAE), 
and rates of satisfaction in a group of morphine-treated postoperative children with ND. We 
hypothesised that children with ND would have a higher risk of both RD and SAE. We have 
previously described the use of morphine-NCA in our institution, including some of the data 
presented here, although previous studies did not address the current hypothesis, and a greater 
number of patients are included here.
2, 18
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Methods 
Nurse-controlled analgesia 
Morphine-NCA is an intravenous morphine infusion using a locked, programmable infusion 
pump, with the option for additional doses (‘boluses’) of morphine administered on demand 
by nursing staff, subject to a lockout period. The NCA protocol is given in Appendix 1.
2, 18
 
Patients receiving morphine-NCA are observed at least hourly during treatment. Pain scores 
were measured with the Wong-Baker Faces Rating Scale,
19
 a 0-10 Numerical Rating Scale,
20
 
FLACC,
21
 revised-FLACC,
22
 COMFORT
23
 or PAT
24
 as appropriate and as these tools 
became available. Sedation was measured using the University of Michigan Sedation Scale.
25
 
Trained nurses are permitted to deliver bolus doses following pain assessment with the aim of 
maintaining pain scores below 4/10 on a numerical rating scale. Simple analgesics, 
paracetamol & NSAID, are prescribed (unless contra-indicated) for all patients and 
administered as appropriate. The administration of supplementary opioid analgesia is 
prohibited during NCA. Naloxone 4 μg kg-¹ is prescribed pro re nata (as needed) for 
administration in the event of clinically significant RD at the discretion of clinical staff. 
Parents and other non-professional carers are not permitted to deliver morphine bolus doses. 
 
Outcomes 
Principal outcomes were: cumulative incidence of RD; cumulative incidence of SAEs; and 
satisfaction with analgesia. RD was defined as depression of respiratory rate below that 
stipulated by the NCA prescriber (a mandatory part of the NCA prescription) as judged and 
documented by the patient’s clinical care team. SAEs were defined as in European Directive 
2001/20 on good clinical practice in clinical trials as any untoward medical occurrence that 
results in death, is life-threatening, requires prolongation of existing hospitalization or results 
in persistent or significant disability or incapacity.
26
 We deemed all instances of naloxone 
6 
administration for RD as SAE. Satisfaction was recorded at the end of treatment as very 
good, good, fair or poor according to assessments made by trained and experienced Clinical 
Nurse Specialists taking into account the opinions of other clinical staff, the family, and 
where possible, the patient. 
 
Patients and data  
We identified all patients aged 0-18 years who received intravenous morphine-NCA 
following major surgery at Great Ormond Street Children’s Hospital, between 1996 and 
2011. Prospectively documented data were collected at least once daily by trained and 
experienced Clinical Nurse Specialists and entered into a pain management case record at the 
bedside which was transcribed, when treatment was completed, to a secure electronic 
database. The database was maintained by trained staff and regularly reviewed; anomalous 
data being independently verified against original hospital records at point of entry.
2
 
Following extraction, data were re-checked for quality and consistency using standard 
graphical and statistical techniques. Institutional registration and approval were obtained 
according to local policies, (Project 1879, Great Ormond Street Hospital Clinical Audit 
Registration, February 2016) and data were processed in accordance with UK information 
governance requirements. 
 
Patients who received morphine-NCA were identified as having ND from the clinical case 
record and divided into two groups: those with ND (NDG) and those without (control group, 
CG). Children were included in the NDG if the ‘developmental delay’ checkbox was 
completed on the case record and/or the clinical diagnosis included medical conditions 
known to cause neurodevelopmental delay, and evidence that the presence of 
neurodevelopmental delay had been confirmed on physical examination. Where possible, the 
7 
NDG was also sub-divided into groups by diagnosis (On-line Table 1). Data were also 
collected on known and theoretical confounders: age; weight; sex; RI; obstructive sleep 
apnoea (OSA); operation duration (minutes); type of surgery (grouped as cardiothoracic, 
general, urological, head and neck, neurosurgery, orthopaedic and plastics); administration of 
intraoperative opioids and dose; postoperative ward location (ward); length of NCA infusion 
(hours); whether the patient was initially commenced on a background infusion and infusion 
rate; initial NCA bolus size; and overall postoperative morphine dose (expressed in μg kg-¹ 
hr
-
¹). The day of surgery is labelled day zero (D0) and is the time between infusion start and 
midnight; subsequent calendar days are labelled day one (D1), etc., until termination of the 
NCA infusion. 
 
Statistical analysis 
A summary of the statistical methods is given here; see the On-line Statistical Appendix for 
full details. Descriptive statistics were computed as median (IQR) and n (%). Possible effect 
modifiers were investigated using stratification. Expectation-maximization with 
bootstrapping using the R package Amelia II
27
 was performed to impute missing values with 
ten imputed datasets. Multilevel logistic regression was used to analyse the incidence of RD 
and SAEs, allowing the intercept to vary by ward. Parameters were estimated using Bayesian 
inference from Markov chain Monte Carlo simulations with Gibbs sampling (see On-line 
Statistical Appendix for details on handling of missing data and Bayesian set-up). Model fit 
was assessed by examining the deviance information criterion (DIC) of each model: lower 
values of the DIC represent better fit; 5 units change indicates some substantial improvement 
and 10 units change definite improvement. As any increase in the risk of RD or SAE was 
considered clinically important, we calculated the probability that the true OR for ND was >1 
8 
in each model by computing the area under the curve of the posterior distribution which 
represented an OR >1. 
 
Satisfaction was dichotomised into ‘Good or Very Good’, and ‘Poor or Fair’, and tested in 
complete case analysis (296 [2.3%] missing satisfaction values were missing) using χ2 (Yates’ 
correction) or Fisher’s Exact as appropriate. 
 
Analysis was conducted in the statistical computing environment R (Vienna, Austria: R 
Foundation for Statistical Computing, 2013) and WinBUGS (Cambridge, UK: Medical 
Research Council Biostatistics Unit, 2003). Data were obtained and analysed on all available 
patients. 
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Results 
Patient demographics and morphine dose 
Twelve thousand, nine hundred and four patients were included; the prevalence of ND was 
19% (n=2,390). There were missing data on the following variables: operation duration 
(n=1,037, 8.0%), intraoperative opioid administration (n=958, 7.4%), infusion background, 
background rate and bolus size (n=44, 0.3% on all three) and overall postoperative morphine 
dose (n=148, 1.1%).  Patient characteristics, operation duration and duration of morphine-
NCA are shown in Table 1 (surgical categories broken down by group are given in On-line 
Table 2). Patients in the NDG were older and heavier (older patients in the control group are 
usually commenced on patient-controlled analgesia), were more likely to have OSA and had 
longer operation and postoperative NCA infusion durations (though these were not 
significantly different to the CG in all subgroups of ND). 
 
Median postoperative morphine dose in the NDG was 16.31 μg kg-¹ hr-¹ on D0, compared to 
15.02 μg kg-¹ hr-¹ in the CG (Table 2). As expected, morphine dose declined with each 
consecutive postoperative day in all groups. Actual values for all opioid doses are given in 
the on-line supplementary materials and were included in the overall analysis. 
 
Respiratory depression 
There were 88 cases of RD; 26 were in the NDG (cumulative incidence: 1.09%) and 62 were 
in the CG (cumulative incidence: 0.59%, Table 3). Further comparison by NDG diagnostic 
subgroup suggested that patients with Cerebral Palsy, Down’s syndrome and encephalopathy 
appear to be most at risk of RD (1.68%, 1.84% and 2.53% vs. 0.59%, Table 3). About half of 
the incidents of RD occurred on D0 and 92% occurred within the first 48 hours (On-line 
10 
Table 7); the pattern was similar in both the NDG and CG. The distribution of RD among the 
covariates and stratified by NDG/CG is given in On-line Tables 8 and 9. 
 
Figure 1A shows the posterior distribution of the effect of neurodevelopmental disability on 
the odds of RD in an unadjusted model. It shows that the odds of RD were 65% (OR 1.65, 
95% CrI 1.03 to 2.63) higher in children in the NDG compared to those in the CG. There was 
a 98% chance that the true OR was >1. 
 
Further models were constructed and the results did not appreciably change; details of these 
models can be found in On-line Table 10 and the respective posterior distributions for the 
effect of ND can be found in On-line Figure 1. In summary, in model 3, the effect of ND was 
augmented to OR 1.79 (1.05 to 3.04) after adjusting for age (age being a very important 
predictor in all models with older patients having a much lower risk of RD than neonates). 
Gender, presence of RI and OSA were not significant. Surgical category was entered in 
model 4 and this attenuated the effect size slightly but surgery was not significant, did not 
improve model fit and so was discarded. In model 5, the administration of intraoperative 
opioids, commencement on a background infusion, NCA bolus size and overall postoperative 
morphine dose on D0 were all not significant predictors of RD. Similarly, in model 6, there 
was no evidence of a time effect with year of surgery being insignificant. 
 
A morphine-ND interaction term was entered and was significant (model 7). This is 
illustrated in Figure 2A, which indicates that the risk of RD in patients in the NDG rose with 
increasing postoperative doses of morphine within a therapeutic range, whereas this did not 
occur in the CG. This model had the best fit of all seven (lowest DIC). 
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The ward intercept SD in the model with no predictors (model 1) showed a degree of 
variability in the odds of RD by ward, which ranged from 0.001 to 0.023. About 62% of this 
variability was due to differences in ages and surgical categories of the patients seen on each 
ward; the remaining variability was not accounted for by the other measured variables. 
 
Serious adverse events 
There were 52 SAEs. Forty nine SAEs were RD treated with naloxone; 3 were judged not 
opioid related. Fourteen SAEs (0.59%) occurred in the NDG vs 38 (0.36%) in the CG 
(absolute risk difference 0.23%). Half of the SAEs occurred on D0 and 92% within the first 
48 hours in both the NDG and CG (On-line Table 7). 
 
The posterior distribution for the OR of ND in the unadjusted SAE model is given in Figure 
1B which shows that those with ND were 1.42 times more likely to experience an SAE, 
though as the 95% CrI crossed 1 (0.77, 2.63) this finding was interpreted as non-significant.  
Results did not change appreciably in further models (On-line Table 11 and On-line Figure 
1).  Age was an important risk factor (as with RD) and none of gender, RI, surgical category, 
intraoperative and postoperative opioid administration or year was significant (models 3 to 
6). There was a shallow interaction between postoperative morphine and ND (model 7) as 
shown in Figure 2B; this model had the best fit. The degree of variability in the risk of SAE 
due to ward was similar to that for RD. 
 
Satisfaction 
Overall, satisfaction was very good or good in 12,320 (98%) cases and fair or poor in 288 
(2%).  Morphine-NCA in the NDG was 1.2% more likely to be rated fair or poor than in the 
CG (3.3% vs 2.1%, χ2 p<0.001). For the ND subgroups, fair or poor ratings patients in the 
12 
Cerebral Palsy group 26 (5.5%, p<0.001) and Developmental Delay 41 (2.9%, p=0.032), 
were also significant. 
13 
Discussion 
This is the first large scale study specifically attempting to quantify, examine and better 
understand the risks of OIRD in children with ND. We compared 2,390 children with ND to 
10,514 without, who were receiving morphine after major surgery and have found that the 
presence of ND, after correcting for confounders, was associated with greater risk of 
experiencing RD:  a significant interaction between ND and postoperative morphine dose was 
also found.  Although RD was more prevalent in the ND group, in the present study there 
appeared to be little or no difference in the risk of experiencing SAE, which is reassuring. 
 
Neurodevelopmental disabilities are a group of congenital or acquired long-term conditions 
that are attributed to impairment of the brain and/or neuromuscular system and create 
functional limitations. Although easily identified clinically, they comprise a heterogeneous 
group where a specific diagnosis is not always ascribed. Such conditions may or may not be 
progressive, occur alone or in combination and in a broad range of severity and complexity. 
Their impact may include difficulties with movement, cognition, hearing and vision, 
communication, emotion, and behaviour.
28
 Children with ND represent a significant 
proportion of children undergoing surgery and therefore postoperative pain, and in fact have 
been considered to be at increased risk of experiencing all types of pain.
17, 29-32
 Despite this, 
few data are available to guide management and in fact they are often specifically excluded 
from research studies, and have been estimated to be represented in only 0.03% of the pain 
literature.
33, 34
  
 
Respiratory depression is often considered to be a predictable side-effect of opioid analgesia; 
but it is the possible progression to cardio-respiratory collapse that could lead to serious 
permanent harm, or even death, that has been identified as the greatest safety concern for 
14 
clinicians.
5, 35
 Fortunately, awareness of this potential, the recognition of ‘at risk’ patient 
groups and provision of appropriate monitoring has likely contributed to the low reported 
rates of serious harm; although there is concern that such low rates, the lack of a generally 
accepted definition of RD, methodological problems in undertaking multi-site population 
studies, under-reporting of individual cases, and the small size of many studies in children, 
may underestimate the true incidence of both respiratory depression and serious 
complications.
35
 In the present single-centre study, we found the overall rates of RD to be 
reassuringly low (0.59-1.09%) but nevertheless slightly above the range of estimates from 
previous multi-site studies.
36
 In strong agreement with previous studies patient age was the 
most consistent and important predictor of RD in all patients in the present study. The finding 
here that the generally accepted risk factors OSA and RI did not predict RD may imply that 
such risks can be successfully attenuated, a concept further supported by the low rate of 
progression to SAE that was observed in all groups. 
 
Aside from the increased risk of RD in children with ND we also observed an increased 
‘sensitivity’ to morphine in the NDG: i.e. patients with ND appeared to be more likely to 
experience RD with increasing morphine dose. The reasons for this are unclear but children 
with ND may have impaired respiratory drive, cardiorespiratory deficits, neuromuscular and 
postural abnormalities, gastro-oesophageal reflux, and are more likely to be treated with anti-
epileptics, muscle relaxants, sedatives, and other medicines that were not controlled for in 
this study.
7, 11
  
 
Whilst providing some data on the incidence and risks of OIRD in patients with ND, previous 
studies have been difficult to interpret owing to differences in study design, patient 
population, opioid drug, route, dosing and dosing frequency, monitoring practices, reporting 
15 
criteria and the lack of control groups.
3, 9, 15, 16, 37, 38
 A small retrospective cohort study by 
Long, Ved and Koh found no differences in the risk of ‘clinically significant oxygen 
desaturation’ (SpO2 < 94%) between a group of children with (n=71) and without (n=77) 
cerebral palsy in the post-anesthesia care unit
9
 whereas Chidambaran and others’ case-control 
study, analysing 38 cases of naloxone administration to inpatients in a tertiary children’s 
hospital reported risk factors <1 year, prematurity, OSA, obesity, underweight, and 
developmental delay.
16
 
 
How profound and what type of ND might greater predispose to RD is not known. In the 
current study, children with cerebral palsy (non-progressive ND due to perinatal causes), 
Down’s syndrome and encephalopathy appear to be at relatively greatest risk of developing 
both RD and SAE. Adverse peri-natal events are known to influence subsequent development 
of respiratory control and so further study of the underlying mechanisms might lead to 
important clues as to potential causation.
39
 However, as firm conclusions regarding relative 
risks in sub-groups were difficult in this study as numbers were too low to perform 
multivariable analysis, further clinical study would also be required. 
 
Strengths and limitations  
While our study was conducted retrospectively using routine clinical data, those data were 
collected prospectively according to a mandatory, rigorous protocol and therefore not subject 
to recall bias. It is possible that the overall prevalence of neurodevelopmental disabilities may 
have been underreported, leading to bias to the null, but as the estimated lifetime prevalence 
of neurological disorders in the UK is 6% the higher prevalence (19%) found here, along with 
the data collection protocol, should have ensured that any effect of underreporting of ND was 
successfully minimised.
40
 SAEs or cases of RD could also have been unreported, we feel that 
16 
this is unlikely as they would have been recorded and investigated at the time they occurred. 
There were a number of potentially relevant variables for which we were unable to adjust for 
example the incidence of RD/SAE may also be driven by provider-level characteristics such 
as the quality and volume of nursing care. Although it was not possible to examine the effect 
of individual nursing teams (e.g., their experience and training) in this analysis, we did model 
the contextual effect of individual wards. 
 
Conclusions & clinical implications 
Morphine-NCA is an acceptable method of postoperative analgesia in children with and 
without ND. Postoperative children with ND appear to be at higher risk of developing OIRD 
with Morphine-NCA than children without ND, although the risk remains low within the 
parameters of this study. Although children with ND did not experience significantly higher 
rates of SAE they were nevertheless 1% more likely to have a less satisfactory rating of 
Morphine-NCA.  
 
(Word count 3,120)
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Figure legends 
 
Figure 1. Posterior distributions of the effect of having neurodevelopmental disability on the risk of respiratory depression (Plot A) and serious 
adverse events (Plot B). CrI, credibility interval; AUC > 1, area under the curve with an odds ratio >1. 
 
 
Figure 2. Plots showing the effect of morphine on the predicted probability of RD events (Plot A), and SAE (Plot B) in the NDG and CGs. 
Dashed lines are 95% credibility intervals (credibility intervals represent the range of plausible predicted probabilities of events  across the stated 
range of morphine doses that are predicted by the final model). RD, respiratory depression; SAE, serious adverse events; NDG, 
neurodevelopmental disability group; CG, control group. 
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Appendix 1: Standard protocol for morphine-NCA 
  
Morphine dose  
Weight Dose Solution Dose per ml 
<50kg 1 mg kg
-1
 50 ml of 0.9% sodium chloride or dextrose 5% 1ml = 20 mcg kg
-1
 
>50kg 50 mg 50 ml of 0.9% sodium chloride or dextrose 5% 1ml = 1 mg 
  
Pump programming  
Background: none*, 0.2, 0.5 or 1 ml h
-1
 (0-20 mcg kg
-1
 h
-1
, max. 1 mg h
-1
) 
Bolus dose: 0.5* or 1 ml (10 or 20 mcg kg
-1
, max. 1 mg) 
Lackout: standard: 20 or 30 min. Intensive care unit only: 5 min. 
  
* Infants and neonates <5kg. 
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Table 1 Patient characteristics, durations of surgery and morphine-NCA by group (NDG and CG) and NDG subgroups. NDG, 
neurodevelopmental disability group; OSA, obstructive sleep apnoea; CG, Control group; CP, cerebral palsy; Dev. delay, developmental delay; 
DS, Down’s syndrome; Enceph., encephalopathy; NTD, neural tube defect; Seizure dis., seizure disorder. 
 
 
Group n Age 
Median (IQR) 
Weight 
Median (IQR) 
Male 
n (%) 
Renal 
impairment 
n (%) 
OSA 
n (%) 
Operation duration 
(minutes) 
Median (IQR) 
Infusion duration 
(hours) 
Median (IQR) 
         
         
CG 10 514 1.67 (0.53, 4.39) 11.00 (7.00, 16.60) 5861 (55.7%) 425 (4.0%) 20 (0.2%) 120.00 (80.00, 160.00) 27.80 (21.00, 48.30) 
         
NDG: all 2390 6.30 (2.25, 11.16) 17.80 (11.00, 28.80) 1281 (53.6%) 89 (3.7%) 21 (0.9%) 135.00 (90.00, 190.00) 40.50 (22.20, 64.00) 
         
         
CP 477 9.60 (5.27, 13.50) 21.80 (14.60, 30.00) 266 (55.8%) 1 (0.2%) 2 (0.4%) 135.00 (90.00, 190.00) 47.00 (28.00, 69.50) 
Dev. delay 1399 5.60 (2.15, 10.51) 17.00 (10.62, 28.75) 759 (54.3%) 77 (5.5%) 15 (1.1%) 140.00 (90.00, 210.00) 37.90 (21.80, 64.00) 
DS 163 4.00 (0.67, 9.03) 13.30 (7.20, 24.00) 90 (55.2%) 3 (1.8%) 3 (1.8%) 120.00 (90.00, 180.00) 29.00 (21.70, 47.00) 
Enceph. 80 3.21 (1.13, 7.73) 12.60 (7.78, 20.00) 37 (46.3%) 1 (1.3%) 1 (1.3%) 130.00 (90.00, 180.00) 40.00 (22.63, 59.00) 
NTD 160 4.53 (0.95, 8.24) 15.00 (9.15, 25.00) 79 (49.4%) 7 (4.4%) 0 (0.0%) 165.00 (108.75, 221.25) 45.00 (22.35, 65.20) 
Seizure dis. 111 7.73 (2.66, 11.82) 26.00 (14.00, 37.65) 51 (45.9%) 0 (0.0%) 0 (0.0%) 180.00 (120.00, 240.00) 23.50 (19.50, 42.50) 
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Table 2 Postoperative morphine dose. Includes only patients without missing morphine data on day 0 (n=12 756, 99%). CG, control group; 
NDG, neurodevelopmental disability group. 
 
 
Group 
n  Median (IQR) morphine dose 
(μg kg-¹ hr-¹) 
D0 D1 D2  D0 D1 D2 
        
CG 10 393 10 009 4366  15.02 (8.92, 23.48) 9.29 (4.48, 15.52) 7.19 (3.41, 13.50) 
        
NDG: all 2363 2294 1267  16.31 (9.22, 26.04) 10.62 (5.51, 17.50) 8.12 (3.93, 14.38) 
        
        
Cerebral palsy 473 465 329  19.84 (12.29, 30.37) 13.08 (8.71, 20.69) 9.15 (4.66, 15.67) 
Developmental delay 1381 1333 695  15.25 (8.52, 25.00) 10.07 (5.11, 16.67) 8.00 (3.72, 14.19) 
Down’s syndrome 161 156 72  15.20 (8.42, 23.56) 8.92 (3.54, 16.21) 6.47 (1.42, 10.41) 
Encephalopathy 78 76 44  18.01 (9.17, 26.78) 9.53 (4.75, 16.51) 5.65 (3.22, 13.00) 
Neural tube defects 160 155 96  18.51 (9.46, 26.92) 11.30 (5.12, 19.78) 8.70 (4.70, 15.51) 
Seizure disorder 110 109 31  12.56 (8.43, 21.45) 8.86 (4.85, 12.97) 6.30 (2.02, 10.21) 
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Table 3 Respiratory depression and serious adverse events by group and sub-group. NDG, neurodevelopmental disability group; CG, control 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              NDG CG 
(n=10 514) 
    
    
    
Respiratory depression NDG: all (n=2390) 26 (1.09%) 62 (0.59%) 
    
    
 Cerebral palsy (n=477) 8 (1.68%)  
 Developmental delay (n=1399) 11 (0.79%)  
 Down’s syndrome (n=163) 3 (1.84%)  
 Encephalopathy (n=80) 2 (2.53%)  
 Neural tube defects (n=160) 2 (1.25%)  
 Seizure disorder (n=111) 0 (0.00%)  
    
Serious adverse events NDG: all (n=2390) 14 (0.59%) 38 (0.36%) 
    
    
 Cerebral palsy (n=477) 6 (1.26%)  
 Developmental delay (n=1399) 4 (0.29%)  
 Down’s syndrome (n=163) 2 (1.23%)  
 Encephalopathy (n=80) 1 (1.25%)  
 Neural tube defects (n=160) 1 (0.63%)  
 Seizure disorder (n=111) 0 (0.00%)  
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On-line Tables 
 
On-line Table 1. Diagnoses of patients with ND (n=2390) where at least 80 patients with the same diagnosis were recorded. Groups where no 
cause was specified or where fewer than 80 patients had a particular diagnosis are grouped as developmental delay. 
 
Diagnosis n 
  
Cerebral palsy 477 
Developmental delay 1399 
Down’s syndrome 163 
Encephalopathy 80 
Neural tube defect 160 
Seizure disorder 111 
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On-line Table 2. Number of patients undergoing each type of surgery broken down by diagnostic category (row percentages). CG, control group; 
NDG, neurodevelopmental disability group. 
 
 
 
Group n Cardiothoracic General Surgery Urology Head & Neck Neurosurgery Orthopaedics Plastics 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
         
         
CG 10 514 1361 (12.9%) 3348 (31.8%) 2185 (20.8%) 1331 (12.7%) 663 (6.3%) 1495 (14.2%) 131 (1.3%) 
         
NDG: all 2390 137 (5.7%) 933 (39.0%) 173 (7.2%) 143 (6.0%) 287 (12.0%) 707 (29.6%) 10 (0.4%) 
         
         
Cerebral palsy 477 3 (0.6%) 200 (41.9%) 9 (1.9%) 2 (0.4%) 6 (1.2%) 257 (53.9%) 0 (0.0%) 
Developmental delay 1399 93 (6.6%) 549 (39.2%) 119 (8.5%) 122 (8.7%) 143 (10.2%) 367 (26.2%) 6 (0.4%) 
Down’s syndrome 163 34 (20.9%) 90 (55.2%) 5 (3.1%) 5 (3.1%) 9 (5.5%) 20 (12.3%) 0 (0.0%) 
Encephalopathy 80 2 (2.5%) 50 (62.5%) 0 (0.0%) 11 (13.8%) 6 (7.5%) 11 (13.8%) 0 (0.0%) 
Neural tube defects 160 1 (0.6%) 19 (11.9%) 37 (23.1%) 0 (0.0%) 60 (37.5%) 39 (24.4%) 4 (2.5%) 
Seizure disorder 111 4 (3.6%) 25 (22.5%) 3 (2.7%) 3 (2.7%) 63 (56.8%) 13 (11.7%) 0 (0.0%) 
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On-line Table 3. Intraoperative opioid administration and dosing. Includes only patients with intraoperative opioid data (n=11,946, 93%). The 
‘other’ category represents a small number of patients who were given diamorphine or codeine. NDG, neurodevelopmental disability group; CG 
control group. * Dose-by-group data were also stratified by age (<12 years and >12 years) and the results were the same (not shown). 
 
Drug NDG 
n (%) or median (IQR) 
CG 
n (%) or median (IQR) 
   
Drug administered   
Any opioid 2001 (89.3%) 8522 (87.8%) 
Morphine 921 (41.1%) 3434 (35.4%) 
Fentanyl 1631 (72.8%) 7121 (73.4%) 
Other 4 (0.2%) 22 (0.2%) 
   
Dose (mg·kg
-1
)*   
Morphine 0.10 (0.07, 0.12) 0.10 (0.06, 0.11) 
Fentanyl 0.003 (0.002, 0.004) 0.003 (0.002, 0.005) 
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On-line Table 4. Morphine dose by surgery in patients in the neurodevelopmental disability group. Includes only patients without missing 
morphine data on day 0 (n=2,363, 99%). 
 
Surgical category 
n  Median (IQR) morphine dose 
(μg kg-¹ hr-¹) 
D0 D1 D2  D0 D1 D2 
        
Cardiothoracic 132 126 52  18.87 (11.92, 29.09) 14.33 (8.92, 21.46) 11.13 (6.54, 18.02) 
General 927 916 613  16.73 (9.95, 26.50) 10.19 (5.33, 16.93) 6.60 (3.14, 11.67) 
Urological 172 161 96  15.64 (7.74, 24.91) 10.00 (5.00, 17.00) 8.29 (3.73, 15.58) 
Head and neck 141 134 10  8.31 (4.98, 12.86) 3.03 (1.25, 6.08) 1.49 (0.00, 4.22) 
Neurosurgery 285 277 83  12.32 (6.67, 21.29) 8.27 (4.63, 13.08) 6.00 (3.28, 10.11) 
Orthopaedic 696 671 411  18.84 (11.96, 28.64) 13.36 (8.50, 21.00) 10.67 (6.15, 17.87) 
Plastics 10 9 2  8.98 (4.38, 22.29) 6.31 (5.83, 12.08) 5.13 (4.84, 5.42) 
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On-line Table 5. Morphine dose by surgery in patients in the control group. Includes only patients without missing morphine data on day 0 
(n=10,393, 99%). 
 
Surgical category 
n  Median (IQR) morphine dose 
(μg kg-¹ hr-¹) 
D0 D1 D2  D0 D1 D2 
        
Cardiothoracic 1332 1281 614  20.25 (12.36, 30.00) 15.25 (10.00, 20.83) 11.09 (6.51, 16.62) 
General 3306 3204 2045  15.00 (8.21, 23.63) 9.09 (4.25, 15.30) 5.75 (2.31, 11.08) 
Urological 2,173 2,103 670  13.64 (8.45, 20.53) 8.02 (4.00, 12.71) 5.87 (3.29, 12.16) 
Head and neck 1,319 1,230 71  10.61 (6.80, 15.80) 4.44 (2.00, 8.01) 3.27 (0.85, 8.18) 
Neurosurgery 651 637 299  19.05 (11.47, 27.06) 11.47 (6.78, 16.92) 7.41 (3.90, 12.58) 
Orthopaedic 1483 1437 632  17.33 (11.11, 26.58) 11.43 (7.23, 18.42) 10.90 (5.20, 20.93) 
Plastics 129 117 35  13.13 (7.65, 19.56) 8.33 (3.90, 13.47) 7.54 (4.14, 11.91) 
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On-line Table 6. Initial background and bolus doses. Includes patients with background and bolus dose data only. NDG, neurodevelopmental 
disability group; CG control group. * The distribution of bolus sizes was bimodal with most patients having either a 10 µg·kg
-1 
or 20 µg·kg
-1 
bolus. A higher proportion of patients in the CG had a bolus size of 10 µg·kg
-1 
(25%) than patients in the NDG (15%), this difference being 
reflected in the lower end of the IQRs. Note also that the distribution of initial background rate was trimodal at the standard settings of 4 µg·kg
-
1
·h
-1
, 10 µg·kg
-1
·h
-1 
and 20 µg·kg
-1
·h
-1
. These data were treated as continuous as any value along a range was theoretically possible and there 
were a number of patients whose bolus sizes and backgrounds were out of the usual protocol.  
 
Program NDG 
n (%) or median (IQR) 
CG 
n (%) or median (IQR) 
   
Commenced on background infusion 1648 (69.0%) 7075 (67.6%) 
Initial background rate (µg·kg
-1
·h
-1
)* 10.0 (4.0, 10.0) 10.0 (4.0, 10.0) 
Initial bolus size (µg·kg
-1
)* 20.0 (20.0, 20.0) 20.0 (10.0, 20.0) 
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On-line Table 7. Day of occurrence of respiratory depression and serious adverse events. NDG neurodevelopmental disability group; CG control 
group. 
 
 
Respiratory depression 
 
Day NDG 
n (%) 
CG 
n (%) 
   
0 13 (50%) 29 (47%) 
1 12 (46%) 27 (44%) 
2 1 (4%) 5 (8%) 
3 0 (0%) 0 (0%) 
4 0 (0%) 1 (2%) 
   
Serious adverse events 
 
Day NDG 
n (%) 
CG 
n (%) 
   
0 9 (64%) 18 (47%) 
1 5 (36%) 16 (42%) 
2 0 (0%) 4 (11%) 
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On-line Table 8. Distribution of respiratory depression and serious adverse events in the neurodevelopmental disability group and control group, 
per predictors. Denominator = number of patients at each predictor level within the neurodevelopmental disability group or control group. NDG, 
neurodevelopmental disability group; CG, control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predictor 
Respiratory depression  Serious adverse events 
 NDG 
n (%) 
CG 
n (%) 
 
NDG 
n (%) 
CG 
n (%) 
       
Age category <1 mo 2/38 (5.3%) 21/583 (3.6%)  1/38 (2.6%) 16/583 (2.7%) 
 1-36 mo 4/690 (0.6%) 26/6118 (0.4%)  2/690 (0.3%) 12/6118 (0.2%) 
 3-6 yr 6/574 (1.0%) 7/2535 (0.3%)  2/574 (0.3%) 5/2535 (0.2%) 
 7-10 yr 4/473 (0.8%) 2/735 (0.3%)  3/473 (0.6%) 1/735 (0.1%) 
 11-15 yr 8/497 (1.6%) 4/472 (0.8%)  5/497 (1.0%) 3/472 (0.6%) 
 >16yr 2/118 (1.7%) 2/71 (2.8%)  1/118 (0.8%) 1/71 (1.4%) 
       
Sex Male 15/1282 (1.2%) 38/5861 (0.6%)  8/1282 (0.6%) 23/5861 (0.4%) 
 Female 11/1108 (1.0%) 24/4653 (0.5%)  6/1108 (0.5%) 15/4653 (0.3%) 
       
Surgery Cardiothoracic 1/137 (0.7%) 4/1363 (0.3%)  1/137 (0.7%) 3/1363 (0.2%) 
 General 13/933 (1.4%) 38/3348 (1.1%)  7/933 (0.8%) 20/3348 (0.6%) 
 Urological 0/173 (0.0%) 6/2185 (0.3%)  0/173 (0.0%) 5/2185 (0.2%) 
 Head and neck 0/143 (0.0%) 5/1331 (0.4%)  0/143 (0.0%) 4/1331 (0.3%) 
 Neurosurgery 1/287 (0.3%) 5/663 (0.8%)  0/287 (0.0%) 5/663 (0.8%) 
 Orthopaedic 11/707 (1.6%) 4/1495 (0.3%)  6/707 (0.8%) 1/1495 (0.1%) 
 Plastics 0/10 (0.0%) 0/131 (0.0%)  0/10 (0.0%) 0/131 (0.0%) 
       
Renal failure Yes 0/89 (0.0%) 3/425 (0.7%)  0/89 (0.0%) 2/425 (0.5%) 
 No 26/2301 (1.1%) 59/10089 (0.6%)  14/2301 (0.6%) 36/10089 (0.4%) 
       
Obstructive sleep Yes 0/21 (0.0%) 1/20 (0.1%)  0/21 (0.0%) 0/20 (0.0%) 
apnoea No 26/2369 (0.0%) 61/10494 (0.0%)  14/2369 (0.0%) 38/10494 (0.0%) 
       
Intraoperative Yes 20/2001 (1.0%) 51/8521 (0.6%)  11/2001 (0.5%) 33/8521 (0.4%) 
opioid No 3/239 (0.8%) 4/1183 (0.3%)  1/240 (0.4%) 2/1183 (0.2%) 
       
Background Yes 21/1648 (1.3%) 32/7075 (0.5%)  11/1648 (0.7%) 18/7075 (0.3%) 
infusion No 5/739 (0.7%) 30/3398 (0.9%)  3/739 (0.4%) 20/3398 (0.6%) 
       
       
37 
 
 
 
On-line Table 9. Associations between postoperative morphine dose (μg · kg-¹ · hr-¹) and respiratory depression and serious adverse events. RD, 
respiratory depression; SAE, serious adverse events; NDG, neurodevelopmental disability group; CG, control group. 
 
 
 
 
 
 
Group 
Respiratory depression  Serious adverse events 
RD 
Median (IQR) 
No RD 
Median (IQR) 
 
SAE 
Median (IQR) 
No SAE 
Median (IQR) 
      
NDG 27.54 (11.41, 36.20) 16.20 (9.23, 25.81)  27.77 (3.42, 39.49) 16.30 (9.23, 25.96) 
CG 10.00 (5.63, 17.39) 15.05 (8.94, 23.53)  10.00 (5.00, 16.20) 15.04 (8.94, 23.53) 
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On-line Table 10 Logistic regression models of respiratory depression. Shaded coefficients are those whose 95% credible intervals (1.96 x SD) do not  
contain 0. All posteriors were approximately Gaussian other than ward intercept SD which was slightly right-skewed. RD, respiratory depression; ND, 
neurodevelopmental disability; DIC, deviance information criterion. 
Outcome  N Predictor 1 2 3 4 5 6 7 
(n, %)   Mean (SD) logistic coefficient estimates from posterior distributions 
          
RD Patients  Intercept -5.31 (0.26) -5.40 (0.27) -3.71 (0.34) -4.20 (0.56) -3.79 (0.53) -3.67 (0.39) -3.42 (0.32) 
(88, 0.69%) 12 904 Neurological deficit (yes vs no)  0.50 (0.24) 0.57 (0.27) 0.51 (0.28) 0.58 (0.27) 0.55 (0.28) -0.30 (0.44) 
  Age <1 mo   Reference Reference Reference Reference Reference 
 Wards  1-36 mo   -2.04 (0.30) -1.91 (0.30) -2.09 (0.34) -2.03 (0.30) -1.95 (0.33) 
 38  3-6 yr   -2.15 (0.39) -1.99 (0.40) -2.21 (0.44) -2.14 (0.39) -2.04 (0.41) 
   7-10 yr   -2.19 (0.52) -2.02 (0.51) -2.22 (0.55) -2.15 (0.52) -2.05 (0.54) 
   11-15 yr   -1.30 (0.43) -1.10 (0.44) -1.35 (0.47) -1.29 (0.44) -1.22 (0.46) 
   16+ yr   -0.88 (0.61) -0.74 (0.61) -0.99 (0.66) -0.89 (0.61) -0.88 (0.66) 
  Gender (Male vs female)   0.16 (0.23)     
  Renal failure (yes vs no)   -0.32 (0.66)     
  Obstructive sleep apnoea (yes vs no)    0.77 (1.28)     
  Surgery Cardiothoracic    Reference    
   General    0.93 (0.56)    
   Urological    -0.18 (0.68)    
   Head, neck & plastics    0.10 (0.71)    
   Neurosurgery    0.30 (0.70)    
   Orthopaedic    0.49 (0.62)    
  Intraoperative opioid (yes vs no)     0.35 (0.39)   
  Background infusion (yes vs no)     0.20 (0.29)   
  Bolus size (per mL)     -0.01 (0.03)   
  Morphine dose D0 (μg kg-¹ hr-¹)     0.00 (0.01)  -0.02 (0.01) 
  Year      0.01 (0.03)  
  Morphine dose x ND interaction       0.04 (0.02) 
          
 Random Ward intercept SD 0.78 (0.26) 0.77 (0.27) 0.48 (0.22) 0.30 (0.22) 0.45 (0.23) 0.45 (0.21) 0.44 (0.22) 
          
  DIC 1032.7 1031.2 1001.7 1000.7 1004.8 1000.5 995.2 
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On-line Table 11 Logistic regression models of serious adverse events. Shaded coefficients are those whose 95% credible intervals (1.96 x SD) do not 
contain 0. All posteriors were approximately Gaussian other than ward intercept SD which was slightly right-skewed. SAE, serious adverse events; ND, 
neurodevelopmental disability; DIC, deviance information criterion. 
 
  
Outcome  N Effects Predictor 1 2 3 4 5 6 7 
(n, %)    Mean (SD) logit coefficient estimates from posterior distributions 
           
SAE Patients  Fixed Intercept -5.81 (0.29) -5.86 (0.28) -3.97 (0.38) -4.23 (0.69) -4.37 (0.74) -3.94 (0.46) -3.58 (0.36) 
(52, 0.40%) 12 904  Neurological deficit (yes vs no)  0.35 (0.31) 0.40 (0.36) 0.39 (0.37) 0.39 (0.37) 0.39 (0.36) -0.78 (0.59) 
   Age <1 mo   Reference Reference Reference Reference Reference 
 Wards   1-36 mo   -2.53 (0.40) -2.47 (0.40) -2.50 (0.44) -2.52 (0.39) -2.29 (0.41) 
 38   3-6 yr   -2.46 (0.48) -2.42 (0.52) -2.44 (0.56) -2.48 (0.50) -2.21 (0.51) 
    7-10 yr   -2.29 (0.61) -2.12 (0.64) -2.20 (0.68) -2.78  (0.60) -1.95 (0.66) 
    11-15 yr   -1.31 (0.50) -1.16 (0.55) -1.25 (0.58) -1.32 (0.51) -1.05 (0.57) 
    16+ yr   -1.32 (0.91) -1.16 (0.93) -1.25 (0.93) -1.27 (0.87) -1.10 (0.92) 
   Gender (Male vs female)   0.12 (0.29)     
   Renal failure (yes vs no)   -0.30 (0.89)     
   Surgery Cardiothoracic    Reference    
    General    0.32 (0.63)    
    Urological    0.09 (0.81)    
    Head, neck & plastics    0.35 (0.84)    
    Neurosurgery    0.53 (0.82)    
    Orthopaedic    -0.13 (0.76)    
   Intraoperative opioid (yes vs no)     0.82 (0.60)   
   Background infusion (yes vs no)     0.21 (0.36)   
   Bolus size (per mL)     -0.02 (0.03)   
   Morphine dose D0 (μg kg-¹ hr-¹)     -0.01 (0.01)  -0.04 (0.02) 
   Year      0.01 (0.03)  
   Morphine x ND interaction       0.06 (0.02) 
           
  Random Ward intercept SD 0.71 (0.29) 0.69 (0.26) 0.44 (0.26) 0.50 (0.29) 0.42 (0.24) 0.43 (0.26) 0.44 (0.24) 
           
   DIC 669.1 669.0 640.1 643.9 641.1 638.1 632.6 
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On-line Figure 1. Posterior distributions of the effect of having neurodevelopmental disability on the risk of respiratory depression (first row) 
and serious adverse events (second row). See On-Line Tables 10 and 11 for details of the models. AUC > 1, area under the curve with an odds 
ratio >1. 
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On-line Statistical Appendix 
 
 
This Appendix gives the full details of the statistical methodology used in the analysis. 
Superscript numbers refer to references at the end of this document and not in the main 
manuscript. All analyses were conducted in R (Vienna, Austria: R Foundation for Statistical 
Computing, 2016) and WinBUGS (Cambridge, UK: Medical Research Council Biostatistics 
Unit, 2003). WinBUGS was interfaced with R using the R2WinBUGS package
1
 and trace 
plots generated using mcmcplots.
2
 All other graphics were created using ggplot2.
3
 Data were 
obtained and analysed on all available patients. 
 
Descriptive statistics 
Descriptive statistics were computed as median (IQR) and n (%). Possible effect modifiers 
were investigated using stratification (On-line Tables 8 and 9). Substantial differences in the 
stratified data were treated as evidence of effect modification and such variables treated as 
candidates for interaction in the regression modelling. Day 0 postoperative morphine dose 
was taken forward in such a way. 
 
Missing data 
There were missing data on the following variables: operation duration (n=1037, 8.0%), 
intraoperative opioid administration (n=958, 7.4%), infusion background, background rate 
and bolus size (n=44, 0.3% on all three) and overall day 0 postoperative morphine dose 
(n=148, 1.1%). The mechanism was considered to be either missing completely at random 
(MCAR; for example, some data were not entered because a chart was missing or illegible 
and these appeared to be isolated incidents) or missing at random (MAR). Missingness for 
operation duration and intraoperative opioid administration, for example, was associated with 
surgical category and no mechanism relating to the missing values was postulated. 
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Given that the MAR/MCAR assumption appeared reasonable, and in order to mitigate the 
loss of power and bias inherent in complete case analysis, expectation-maximisation multiple 
imputation with bootstrapping using the R package Amelia II
4
 was performed to impute 
missing values with ten imputed datasets. The imputation model was given flat priors (the 
default in Amelia II) though logical bounds were set as appropriate to ensure impossible 
values were not imputed. Lognormal variables were transformed during the imputation 
process and histograms of the observed data overlaid with density curves of the imputed data 
indicated that the imputations were reasonable. Where models were constructed from 
imputed datasets, parameter and variance estimates were combined using Rubin’s rules.  
 
Regression modelling: Bayesian set-up 
Multilevel logistic regression was used to analyse the incidence of RD and SAEs. Because of 
the complexity of these models, we used Markov chain Monte Carlo simulations with Gibbs 
sampling to carry out Bayesian inference of model parameters. All estimands, other than 
level-two variance, were given non-informative normally distributed priors (mean 0, 
precision
*
 0.01 or 0.001—a smaller precision was required for some parameters as the larger 
sometimes failed). Level-two variance was ~ N(0, σα) where the hyperparameter σα was ~ 
U(0, 10) to coerce it to a positive value.
5
 Our use of non-informative priors was motivated by 
a lack of available information on which to reliably base informative ones. 
 
Three chains were simulated with randomly generated overdispersed starting values and with 
a sufficient number of burn-in and substantive iterations until convergence. For the most 
complex models, 4000 burn-in and 22 000 further iterations were adequate. Convergence was 
                                                 
*
 Precision is the inverse of the variance and therefore a precision of 0.001 = a variance of 1/0.001 = 1,000. 
Precision is simply the way in which the normal distribution is parameterised in BUGS. 
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assessed by visually examining trace plots and by ensuring that, for all parameters, the 
Gelman-Rubin  statistic was <1.1. 
 
Regression modelling: model specification 
Models were constructed in the following order: first, a null intercept-only model. Whether 
the patient had ND was then entered and retained in all subsequent models. Variables were 
then added in conceptually appropriate groups: age, gender, renal failure and obstructive 
sleep apnoea; surgical category; intraoperative and postoperative morphine 
administration/doses; and, in order to account for unmeasured changes in practice over time, 
year. Predictors were discarded if their 95% credible intervals contained 0. Where there was 
evidence of effect modification, this was tested after constructing the main effects models by 
entering an interaction term.  
 
In all models, the intercept was allowed to vary by ward. This was necessary to account for 
the structured nature of the data (patients nested in wards). This also enables the examination 
of inter-ward variation and accounts for unmeasured provider-level factors which may 
influence the risk of RD/SAE. 
 
Model fit was assessed by examining the deviance information criterion (DIC) of each model. 
The DIC is a goodness of fit measure which accounts for model complexity: lower values 
represent better fit; a change in five units indicates some substantial improvement and a 
change in ten units indicates definite improvement. 
 
Operation duration was omitted from the models as it was felt that including it would have 
been an over-adjustment beyond type of surgery and intraoperative opioid administration. We 
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did not include dose of intraoperative opioid because although patients in the NDG were 
more likely to receive intraoperative morphine (On-line Table 3), there were no differences 
between the two groups in doses; we therefore only included a binary variable indicating 
whether or not each patient received opioids during surgery. A binary variable indicating 
whether the patient was started with a background infusion, and not the background rate, was 
included for the same reason. Finally, OSA was not entered into the SAE model because 
there were no patients with OSA who experienced an SAE (On-line Table 7). 
 
The posterior distributions for parameter estimates are presented with their mean and SD. The 
mean gives the most likely value of each parameter, which in turns represents the change in 
the log-odds of RD with each unit increase in the predictor; analogously to classical logistic 
regression, the exponent of the null model intercept gives the baseline odds and coefficients 
can be exponentiated to obtain odds ratios (though presence of interaction terms complicates 
interpretation). In every model, the ward intercept SD is a measure of the extent to which the 
risk of RD varies by ward (after taking into account the variables in the model). Figure 2 of 
the manuscript was generated by taking 1000 simulated draws from the posterior distributions 
of the logit estimates. The dashed lines represent 95% credibility limits obtained from the 
2.5
th
 and 97.5
th
 percentiles of the posterior draws. 
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